Gliatilin - instructions for use, dose, side effects, contraindications

composition of the capsule shell: gelatin, ezitol, sorbitan, sodium ethyl parahydroxybenzoate, sodium propyl parahydroxybenzoate, titanium dioxide (E171), iron (III) meta-hydroxide (E172)

Solution for intravenous and intramuscular injection

Each ampoule (4 ml) contains: active ingredient - choline alfoscerate - 1000 mg; inactive ingredients - water for injections.

Description:

Capsule: oval yellow opaque soft gelatin capsules containing a viscous colorless solution

Solution for intramuscular and intravenous administration: clear, colorless, odorless solution

Pharmacotherapeutic group:Nootropic remedy

ATX: & nbsp

N.07.A.X.02 Choline alfoscerate

Pharmacodynamics:

Gliatilin - choline alphoscerate is a holinomimetic of central action with a predominant effect on the central nervous system.

The composition of the drug includes 40.5% of choline released from the compound in the brain; Choline is involved in the biosynthesis of acetylcholine (one of the main neurotransmitter mediators). Alphoscerate is biotransformed to glycerophosphate, which is a precursor of phospholipids.

Acetylcholine positively affects the transmission of nerve impulses, and glycerophosphate is involved in the synthesis of phosphatidylcholine (membrane phospholipid), resulting in improved membrane elasticity and receptor function. Gliatilin increases cerebral blood flow, enhances metabolic processes and activates the structures of the reticular formation of the brain, and also restores consciousness in traumatic brain lesions.

Provides a preventive and corrective effect on the factors of involuntary psychoorganic syndrome, such as changes in the phospholipid composition of neuronal membranes and a decrease in cholinergic activity.

Thus, pharmacodynamic studies have shown that Gliatilin acts on: synaptic, including cholinergic transmission of the nerve impulse (neurotransmission); plasticity of the neural membrane; function of receptors.

Pharmacokinetics:Absorption on intake - 88%; easily penetrates the blood-brain barrier, accumulates mainly in the brain (concentration in the brain reaches 45% of the blood level), lungs and liver; 85% is excreted by the lungs in the form of carbon dioxide, the rest (15%) is excreted by the kidneys and through the intestine.

Does not affect the reproductive cycle, does not have a teratogenic and mutagenic effect.

Indications:

- an acute period of craniocerebral injury, mainly with stem lesions (including in cases of impaired consciousness, coma);

- disorders of cerebral circulation according to the ischemic type (acute and recovery period) and hemorrhagic type (recovery period);

- Degenerative and involuntary psycho-organic syndromes and consequences of cerebrovascular insufficiency, such as primary and secondary impairments of mnestic functions, characterized by memory impairment, confusion, disorientation, decreased motivation, initiative, and decreased concentration;

- changes in the emotional and behavioral sphere: emotional lability, increased irritability, decreased interest, senile pseudomelanchia;

- multi-infarct dementia.

Contraindications:Hypersensitivity to the components of the drug.

Pregnancy and lactation:

The use of Gliatilin during pregnancy and lactation (breastfeeding) is contraindicated.

Dosing and Administration:

Injection intramuscularly or intravenously (drip).

Capsules are taken orally before meals.

Adults:

- in acute conditions: intramuscularly in a dose of 1000 mg (1 ampoule) per day or intravenously from 1000 mg to 3000 mg per day. With intravenous administration, the contents of one ampoule (4 ml) are diluted in 50 ml of physiological saline, the infusion rate is 60-80 drops per minute. Duration of treatment is usually 10 days, but if necessary, treatment can continue until the appearance of positive dynamics and the ability to go to the reception inside the capsules.

- with chronic cerebrovascular insufficiency, changes in emotional and behavioral sphere and multi-infarct dementia the drug is prescribed by mouth 400 mg (1 capsule) 3 times a day.

The duration of therapy is 3-6 months.

Side effects:

Nausea (as a consequence of dopaminergic activation), in this case, reduce the dose of the drug. Allergic reactions are possible.

As a rule, the drug is well tolerated even with prolonged use.

Overdose:

Symptoms: nausea.

When this symptom appears, it is recommended to lower the dose of the drug.

Interaction:Drug interaction of the drug Gliatilin is not established.

Effect on the ability to drive transp. cf. and fur:Gliatilin does not affect the patient's ability to engage in potentially hazardous activities.

Form release / dosage:Capsules 400 mg, solution for intramuscular and intravenous administration 250 mg / ml.

Packaging:

Capsules: 400 mg 14 capsules in PVC / aluminum blister; 1 blister and instructions for use in a pack of cardboard. Solution for intravenous and

Solution for intramuscular and intravenous administration: 1000 mg / 4 ml in ampoules of neutral colorless glass; 1 or 3 ampoules in the contour cells together with instructions for use in the pack cardboard.

Storage conditions:

List B.

Capsules: at a temperature not exceeding 25 ° C

Solution for intramuscular and intravenous administration: at a temperature of no higher than 25 ° C.

Keep out of the reach of children!

Shelf life:

Capsules: 3 years.

Solution for intramuscular and intravenous administration: 5 years.Do not use after the expiration date indicated.

Terms of leave from pharmacies:On prescription

Registration number:П N011966 / 02

Date of registration:17.12.2007

Expiration Date:Unlimited

The owner of the registration certificate:Italfarmaco SpAItalfarmaco SpA Italy

Manufacturer: & nbsp

ITALFARMACO, S.p.A. Italy

Representation: & nbspFARMAKOR PRODUCTION LLC FARMAKOR PRODUCTION LLC Russia

Information update date: & nbsp26.04.2017

Illustrated instructions

Instructions

Gliatilin (Gliatilin)